Timing of patient-reported outcomes assessment of transient symptomatic toxicities from myeloma treatment seems to matter – findings from an Nordic Myeloma Study Group phase II relapse trial.

Publikation: KonferencebidragKonferenceabstrakt til konferenceForskningpeer review

  • Henrik Eshøj, Quality of Life Research Center, Department of Haematology, Odense University Hospital, Danmark
  • Lene Kongsgaard Nielsen
  • Anu Partanen, Kuopio University Hospital, Kuopio, Finland., Finland
  • Anu Räsänen, Kymenlaakso Central Hospital, Kotka, Finland
  • Anu Sikiö, Central Finland Central Hospital, Finland
  • Marita Nurmi, Central Finland Central Hospital, Finland
  • Marjaana Säily, Department of Hematology, Oulu University Hospital, Oulu, Finland
  • Sören Möller, Syddansk Universitet
  • ,
  • Raija Silvennoinen, Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Danmark
OriginalsprogEngelsk
Udgivelsesårsep. 2019
StatusUdgivet - sep. 2019
BegivenhedNordic Myeloma Study Group plenary meeting - Copenhagen, Danmark
Varighed: 5 sep. 20196 sep. 2019

Konference

KonferenceNordic Myeloma Study Group plenary meeting
LandDanmark
ByCopenhagen
Periode05/09/201906/09/2019

    Forskningsområder

  • myelomatose

Se relationer på Aarhus Universitet Citationsformater

ID: 191185383